Chat with us
Research Assistance
Online
  • Please enter your first name.

India Gastrointestinal Therapeutics Market, 2025-2033

The gastrointestinal therapeutics market in India is expected to reach a projected revenue of US$ 1,970.3 million by 2033. A compound annual growth rate of 4.8% is expected of India gastrointestinal therapeutics market from 2026 to 2033.

  • Pharmaceuticals
    • GI therapeutics
      • gastrointestinal therapeutics market
Revenue, 2025 (US$M)
$1,354.8
Forecast, 2033 (US$M)
$1,970.3
CAGR, 2026 - 2033
4.8%
Report Coverage
India
India Gastrointestinal Therapeutics Market, 2021-2033 (US$M)

This page contains premium content. Request sample data or start your free trial to explore Horizon.

  • ✔ Access to global market statistics
  • ✔ Access to company profiles
  • ✔ Free use-cases & research insights

No credit card required*

Global Market

Related Markets

Prism AI by Grand View ResearchFree to try

Ask a question about the gastrointestinal therapeutics market

Every figure cited from GVR research

India gastrointestinal therapeutics market highlights

  • The India gastrointestinal therapeutics market generated a revenue of USD 1,354.8 million in 2025 and is expected to reach USD 1,970.3 million by 2033.
  • The India market is expected to grow at a CAGR of 4.8% from 2026 to 2033.
  • In terms of segment, branded was the largest revenue generating drug type in 2025.
  • Generics is the most lucrative drug type segment registering the fastest growth during the forecast period.


Gastrointestinal therapeutics market data book summary

Market revenue in 2025USD 1,354.8 million
Market revenue in 2033USD 1,970.3 million
Growth rate4.8% (CAGR from 2026 to 2033)
Largest segmentBranded
Fastest growing segmentGenerics
Historical data2021 - 2024
Base year2025
Forecast period2026 - 2033
Quantitative unitsRevenue in USD million
Market segmentationBranded, Generics
Key market players worldwideAbbVie Inc, AstraZeneca PLC, Bausch Health Companies Inc, Takeda Pharmaceutical Co Ltd, Pfizer Inc, Bayer AG, Abbott Laboratories, Janssen Pharmaceuticals, Sun Pharmaceutical Industries, Cipla Ltd DR, Gilead Sciences Inc, Biogen Inc, Organon & Co Ordinary Shares


Other key industry trends

  • In terms of revenue, India accounted for 3.2% of the global gastrointestinal therapeutics market in 2025.
  • Country-wise, U.S. is expected to lead the global market in terms of revenue in 2033.
  • In Asia Pacific, China gastrointestinal therapeutics market is projected to lead the regional market in terms of revenue in 2033.
  • China is the fastest growing regional market in Asia Pacific and is projected to reach USD 4,394.9 million by 2033.

The gastrointestinal therapeutics market in India is anticipated to grow exponentially due to international collaborations & partnerships to introduce advanced therapeutics into the market. In addition, presence of skilled physicians & workforce and rising healthcare expenditure are some of the major growth factors that can be attributed to the lucrative market growth.

Furthermore, rising prevalence of GERD, IBD, & IBS, growing disposable income, and rising R&D activities for the aforementioned diseases are other factors expected to contribute to growth of the market.

No credit card required*

Publish Date: Mar 20, 2026

Customize the Report

20% free customization

Include
Countries, segments, points
Tailor
To your product definition
Extend
Deeper competitor detail
Or
A fully bespoke study

Horizon in a snapshot

  • 30K+ Global Market Reports
  • 120K+ Country Reports
  • 1.2M+ Market Statistics
  • 200K+ Company Profiles
  • Industry insights and more

Gastrointestinal Therapeutics Market Companies

NameProfile# EmployeesHQWebsite
Abbott LaboratoriesView profile 114,000100 Abbott Park Road, Abbott Park, IL, United States, 60064-6400www.abbottinvestor.com
AbbVie IncView profile 50,0001 North Waukegan Road, North Chicago, IL, United States, 60064-6400www.abbvieinvestor.com
Pfizer IncView profile 88,00066 Hudson Boulevard East, New York, NY, United States, 10001-2192www.pfizer.com
Cipla Ltd DRView profile 38,955Ganpatrao Kadam Marg, Cipla House, Peninsula Business Park, Lower Parel, Mumbai, MH, India, 400 013www.cipla.com
Bayer AGView profile 99,723Kaiser-Wilhelm-Allee 1, Leverkusen, NW, Germany, 51368www.bayer.com
Sun Pharmaceutical IndustriesView profile 10001+Mumbai, Maharashtra, India, Asiawww.sunpharma.com
AstraZeneca PLCView profile 89,9001 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge, United Kingdom, CB2 0AAwww.astrazeneca.com
Gilead Sciences IncView profile 18,000333 Lakeside Drive, Foster, CA, United States, 94404www.gilead.com
Biogen IncView profile 7,570225 Binney Street, Cambridge, MA, United States, 02142www.biogen.com
Takeda Pharmaceutical Co LtdView profile 49,0951-1, Nihonbashi-Honcho 2-Chome, Chuo-ku, Tokyo, Japan, 103-8668www.takeda.com

India gastrointestinal therapeutics market

The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to Gastrointestinal Therapeutics Market will help companies and investors design strategic landscapes.


Branded was the largest segment with a revenue share of 60.52% in 2025.

Horizon Databook has segmented the India gastrointestinal therapeutics market based on branded, generics covering the revenue growth of each sub-segment from 2021 to 2033.




The gastrointestinal therapeutics market in India is anticipated to grow exponentially due to international collaborations & partnerships to introduce advanced therapeutics into the market. In addition, presence of skilled physicians & workforce and rising healthcare expenditure are some of the major growth factors that can be attributed to the lucrative market growth.

Furthermore, rising prevalence of GERD, IBD, & IBS, growing disposable income, and rising R&D activities for the aforementioned diseases are other factors expected to contribute to growth of the market.

  • India Gastrointestinal Therapeutics Market Drug Type Outlook (Revenue, USD Million , 2021-2033)
    • Branded
    • Generics
  • India Gastrointestinal Therapeutics Market Drug Class Outlook (Revenue, USD Million , 2021-2033)
    • Aminosalicylates
    • Digestive Enzymes
    • Proton Pump Inhibitors
    • Laxatives
    • Anti-emetics
    • H2 Antagonists
    • Anti-diarrheals
    • Biologics/Biosimilar
    • Other Drug Classes
  • India Gastrointestinal Therapeutics Market Route of Administration Outlook (Revenue, USD Million , 2021-2033)
    • Oral
    • Injectables
    • Others Route of Administrations
  • India Gastrointestinal Therapeutics Market Application Outlook (Revenue, USD Million , 2021-2033)
    • Crohn's disease
    • Ulcerative colitis
    • GERD
    • IBS
    • Others Applications
  • India Gastrointestinal Therapeutics Market Distribution Channel Outlook (Revenue, USD Million , 2021-2033)
    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies

Reasons to subscribe to gastrointestinal therapeutics market databook

  • Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
  • Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
  • Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
  • Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
  • Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.

Target buyers of gastrointestinal therapeutics market databook

  • Our clientele includes a mix of gastrointestinal therapeutics market companies, investment firms, advisory firms & academic institutions.
  • 30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
  • Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
  • The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.

Horizon Databook provides a detailed overview of country-level data and insights on the India gastrointestinal therapeutics market, including forecasts for subscribers. This country databook contains high-level insights into India gastrointestinal therapeutics market from 2021 to 2033, including revenue numbers, major trends, and company profiles.

India Gastrointestinal Therapeutics Market, 2021-2033 (US$M)

No Access Stack Chart

India gastrointestinal therapeutics market statistics, by drug type, 2021-2033 (US$M)

No Access Pie Chart

India gastrointestinal therapeutics market statistics, by drug type, 2021-2033 (USD Million)

No Access

Sign up - it's easy, and free!

Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our free plan indefinitely.

Included in Horizon account

  • 30K+ Global Market Reports
  • 120K+ Country Reports
  • 1.2M+ Market Statistics
  • 200K+ Company Profiles
  • Industry insights and more